Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 1
1984 1
1985 1
1987 1
1989 2
1990 4
1991 4
1992 4
1993 4
1994 6
1995 2
1997 6
1998 4
1999 3
2000 3
2001 2
2002 5
2003 4
2004 3
2005 1
2006 1
2007 3
2008 2
2009 1
2010 2
2011 2
2013 2
2014 1
2015 1
2016 2
2017 3
2018 6
2019 4
2020 3
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

95 results
Results by year
Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: lennard a. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. Among authors: lennard a. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Among authors: lennard a. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
lnterleukin-1 Receptor Antagonist.
Lennard AC. Lennard AC. Crit Rev Immunol. 2017;37(2-6):531-559. doi: 10.1615/CritRevImmunol.v37.i2-6.160. Crit Rev Immunol. 2017. PMID: 29773033 Review.
Interleukin-1 receptor antagonist.
Lennard AC. Lennard AC. Crit Rev Immunol. 1995;15(1):77-105. doi: 10.1615/critrevimmunol.v15.i1.30. Crit Rev Immunol. 1995. PMID: 8519423 Review.
Stem cell transplantation.
Lennard AL, Jackson GH. Lennard AL, et al. BMJ. 2000 Aug 12;321(7258):433-7. doi: 10.1136/bmj.321.7258.433. BMJ. 2000. PMID: 10938056 Free PMC article. Review. No abstract available.
Management of non-Hodgkin's lymphomas.
Mounter PJ, Lennard AL. Mounter PJ, et al. Among authors: lennard al. Postgrad Med J. 1999 Jan;75(879):2-6. doi: 10.1136/pgmj.75.879.2. Postgrad Med J. 1999. PMID: 10396578 Free PMC article. Review.
A deconvolutional Bayesian mixing model approach for river basin sediment source apportionment.
Blake WH, Boeckx P, Stock BC, Smith HG, Bodé S, Upadhayay HR, Gaspar L, Goddard R, Lennard AT, Lizaga I, Lobb DA, Owens PN, Petticrew EL, Kuzyk ZZA, Gari BD, Munishi L, Mtei K, Nebiyu A, Mabit L, Navas A, Semmens BX. Blake WH, et al. Among authors: lennard at. Sci Rep. 2018 Aug 30;8(1):13073. doi: 10.1038/s41598-018-30905-9. Sci Rep. 2018. PMID: 30166587 Free PMC article.
95 results